The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis
Top Cited Papers
- 25 September 2003
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 349 (13) , 1207-1215
- https://doi.org/10.1056/nejmoa031975
Abstract
Parathyroid hormone increases bone strength primarily by stimulating bone formation, whereas antiresorptive drugs reduce bone resorption. We conducted a randomized, double-blind clinical study of parathyroid hormone and alendronate to test the hypothesis that the concurrent administration of the two agents would increase bone density more than the use of either one alone.Keywords
This publication has 21 references indexed in Scilit:
- The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With OsteoporosisJournal of Bone and Mineral Research, 2003
- IX: Summary of Meta-Analyses of Therapies for Postmenopausal OsteoporosisEndocrine Reviews, 2002
- III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal OsteoporosisEndocrine Reviews, 2002
- II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal WomenEndocrine Reviews, 2002
- Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2001
- Parathyroid Hormone as a Therapy for Idiopathic Osteoporosis in Men: Effects on Bone Mineral Density and Bone MarkersJournal of Clinical Endocrinology & Metabolism, 2000
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled TrialJAMA, 1999
- Interim Report and Recommendations of the World Health Organization Task-Force for OsteoporosisOsteoporosis International, 1999
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996